Immunization with H1, HASPB1 and MML Leishmania proteins in a vaccine trial against experimental canine leishmaniasis.
about
Single dose novel Salmonella vaccine enhances resistance against visceralizing L. major and L. donovani infection in susceptible BALB/c miceN-Myristoyltransferase from Leishmania donovani: Structural and Functional Characterisation of a Potential Drug Target for Visceral LeishmaniasisLeishmania-specific surface antigens show sub-genus sequence variation and immune recognitionClinical and parasitological protection in a Leishmania infantum-macaque model vaccinated with adenovirus and the recombinant A2 antigenBiomarkers of safety and immune protection for genetically modified live attenuated leishmania vaccines against visceral leishmaniasis - discovery and implications.Babassu aqueous extract (BAE) as an adjuvant for T helper (Th)1-dependent immune responses in mice of a Th2 immune response-prone strain.The protective immune response produced in dogs after primary vaccination with the LiESP/QA-21 vaccine (CaniLeish®) remains effective against an experimental challenge one year later.Polymorphism in the HASPB repeat region of East African Leishmania donovani strainsComparison of visceral leishmaniasis diagnostic antigens in African and Asian Leishmania donovani reveals extensive diversity and region-specific polymorphismsVaccines for canine leishmaniasis.KSAC, the first defined polyprotein vaccine candidate for visceral leishmaniasisTherapeutic vaccination with recombinant adenovirus reduces splenic parasite burden in experimental visceral leishmaniasis.Clinical, hematological and biochemical alterations in hamster (Mesocricetus auratus) experimentally infected with Leishmania infantum through different routes of inoculation.Characterization of the biology and infectivity of Leishmania infantum viscerotropic and dermotropic strains isolated from HIV+ and HIV- patients in the murine model of visceral leishmaniasis.New Insights Into the Transmissibility of Leishmania infantum From Dogs to Sand Flies: Experimental Vector-Transmission Reveals Persistent Parasite Depots at Bite SitesDNA vaccination with KMP11 and Lutzomyia longipalpis salivary protein protects hamsters against visceral leishmaniasisA prime/boost DNA/Modified vaccinia virus Ankara vaccine expressing recombinant Leishmania DNA encoding TRYP is safe and immunogenic in outbred dogs, the reservoir of zoonotic visceral leishmaniasisFML vaccine against canine visceral leishmaniasis: from second-generation to synthetic vaccine.Optimized subunit vaccine protects against experimental leishmaniasis.Recovery of antigen-specific T cell responses from dogs infected with Leishmania (L.) infantum by use of vaccine associated TLR-agonist adjuvant.Trafficking and release of Leishmania metacyclic HASPB on macrophage invasion.Protective immunity using MPL-A and autoclaved Leishmania donovani as adjuvants along with a cocktail vaccine in murine model of visceral leishmaniasis.Resequencing of the Leishmania infantum (strain JPCM5) genome and de novo assembly into 36 contigs.Scientific Opinion on canine leishmaniosisVaccines for canine leishmaniasisSearching Genes Encoding Leishmania Antigens for Diagnosis and Protection
P2860
Q27305906-967E2B8E-314C-4DE1-B380-98E6D598020CQ27658775-90C7188D-4C6F-458D-AE2C-60165520084BQ28475610-554AEE45-52C5-418D-8DAB-FA3D6BBD26D6Q28539852-58840895-04C6-4867-89A5-9B249D39DDEBQ33659753-A590A321-37F6-4F0F-A95F-3EC7A6AC01AFQ33806434-749BD26B-7208-4E46-986A-965A943CFEB8Q33861384-40B78D20-27A5-4418-B584-191C3DA43C74Q34566085-25A88A2D-6FDA-49A6-986B-1048CA150A75Q34613574-A06746DA-2920-499E-BB09-502E5B154A70Q34979934-C6BD5822-B4D7-4F78-8B09-1CAC3A32E1BAQ35138682-54AF2B32-C4BA-4A5D-8B8B-33DB9B409415Q35741989-AA5D8694-A8D1-4C85-81CB-4E3D47210327Q36749036-ED89876A-E953-4EC0-933C-78EC50CB2E48Q36831544-B04B08D2-2175-4EAD-A44D-55BF1D23D084Q36871944-631F805D-3048-44CF-BDC2-749D159D817FQ37106270-3E7E6A14-2D65-4DC0-9AED-DF3164D5DEA9Q37144722-048E78B4-6051-4AF3-9C40-CD7013E735ECQ37229935-94A1CD69-2A5D-4D50-BEDD-865441689B0CQ37439440-F4CE00C0-F01F-4434-A816-899472D24815Q40528471-C3DA00DB-78F7-4EC3-94A8-A21D5A58EC56Q41413341-D05298AF-AFE4-4622-B1DE-977D488A0398Q42653980-9343C9A6-596F-439D-B98F-6CEC6CD1CFD2Q47095097-788E3E83-342D-46FE-85A1-3A01AA66EAF9Q47156873-544571F0-CC1B-477D-867D-D753D56D54BAQ56769198-2BF4AA12-31D8-4DC1-85D2-CCF916956776Q58647150-C9476283-348A-4849-A887-5094DB613E87
P2860
Immunization with H1, HASPB1 and MML Leishmania proteins in a vaccine trial against experimental canine leishmaniasis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 04 June 2007
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Immunization with H1, HASPB1 a ...... rimental canine leishmaniasis.
@en
Immunization with H1, HASPB1 a ...... rimental canine leishmaniasis.
@nl
type
label
Immunization with H1, HASPB1 a ...... rimental canine leishmaniasis.
@en
Immunization with H1, HASPB1 a ...... rimental canine leishmaniasis.
@nl
prefLabel
Immunization with H1, HASPB1 a ...... rimental canine leishmaniasis.
@en
Immunization with H1, HASPB1 a ...... rimental canine leishmaniasis.
@nl
P2093
P2860
P50
P1433
P1476
Immunization with H1, HASPB1 a ...... erimental canine leishmaniasis
@en
P2093
C Cañavate
C Chicharro
P2860
P304
P356
10.1016/J.VACCINE.2007.05.010
P407
P577
2007-06-04T00:00:00Z